Epidermal growth factor receptor G719X mutant (EGFR G719X)

The Epidermal Growth Factor Receptor (EGFR) G719X mutation represents a group of uncommon mutations occurring in exon 18 of the EGFR gene, where glycine at position 719 is substituted by alanine (G719A), cysteine (G719C), or serine (G719S) (My Cancer Genome, 2023). These mutations are located within the P-loop of the tyrosine kinase domain, leading to a conformational change that destabilizes the inactive state and promotes the active state of the receptor, resulting in constitutive downstream signaling through pathways such as MAPK and PI3K/AKT (Kobayashi et al., 2016, Cancer Cell). In the context of non-small cell lung cancer (NSCLC), G719X mutations account for approximately 1.5% to 3% of all EGFR-mutant cases and are often associated with a distinct clinical profile compared to common sensitizing mutations like exon 19 deletions (Yang et al., 2015, Lancet Oncology). While first-generation tyrosine kinase inhibitors (TKIs) like gefitinib show limited efficacy, second-generation irreversible TKIs such as afatinib and third-generation TKIs like osimertinib have demonstrated significant clinical activity against these variants (Cho et al., 2020, Journal of Clinical Oncology). Therapeutic management is often complicated by the frequent occurrence of G719X as part of compound mutations, where it co-exists with other EGFR alterations, potentially altering drug sensitivity (Beau-Faller et al., 2014, Annals of Oncology). Monitoring for these mutations is critical for personalizing treatment, as patients with G719X mutations generally derive greater benefit from specific irreversible inhibitors than from standard chemotherapy or early-generation reversible TKIs.

Other names

EGFR G719AEGFR G719CEGFR G719SErbB1 G719XHER1 G719XEGFR exon 18 mutation

Irreversible or reversible inhibition of the intracellular tyrosine kinase domain of the epidermal growth factor receptor, which prevents ATP binding, autophosphorylation, and the subsequent activation of downstream oncogenic signaling pathways.